Key result
Novel biological strategies currently under development may eventually impact the management of atrial fibrillation, offering potential alternatives to traditional pharmacological therapies.
This review discusses novel biological strategies currently under development for the management of atrial fibrillation.
These approaches warrant no immediate clinical adoption in AF; leaves open their potential to extend therapeutic options.
Atrial fibrillation is a prominent cause of morbidity and mortality in developed countries. Current treatment strategies center on controlling heart rate while allowing fibrillation to persist or targeting fibrillation primarily and attempting to maintain sinus rhythm. Pharmacological therapies are largely successful for rate control, although mild toxicities are common. Rhythm control strategies are often unsuccessful, leaving patients in atrial fibrillation despite attempts to maintain sinus rhythm. This review will discuss novel biological strategies that are currently under development and may eventually have impact on the management of atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Amit et al. (2008) conducted a review in Atrial fibrillation. Biological therapies was evaluated. Novel biological strategies currently under development may eventually impact the management of atrial fibrillation, offering potential alternatives to traditional pharmacological therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: